IL157816A0
(en)
|
2001-03-12 |
2004-03-28 |
Roberto Pellicciari |
Steroids as agonists for fxr
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
DK1734970T3
(en)
|
2004-03-12 |
2015-02-16 |
Intercept Pharmaceuticals Inc |
Treatment of fibrosis using FXR ligands
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
EP2040713B1
(de)
|
2006-06-27 |
2014-06-18 |
Intercept Pharmaceuticals Inc. |
Gallensäurederivate als fxr-liganden zur prävention oder behandlung fxr-vermittelter erkrankungen oder leiden
|
EP1886685A1
(de)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
|
MX2009007728A
(es)
|
2007-01-19 |
2009-12-15 |
Intercept Pharmaceuticals Inc |
Acidos biliares 23-sustituidos como moduladores de tgr5 y metodos de uso de los mismos.
|
US8338628B2
(en)
*
|
2007-08-28 |
2012-12-25 |
City Of Hope |
Method of synthesizing alkylated bile acid derivatives
|
EA020310B1
(ru)
|
2008-07-30 |
2014-10-30 |
Интерсепт Фармасьютикалз, Инк. |
Модуляторы рецептора tgr5 и их применение
|
US8114862B2
(en)
|
2008-11-19 |
2012-02-14 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
US20110257139A1
(en)
|
2008-12-19 |
2011-10-20 |
Royal College Of Surgeons In Ireland |
Treatment of diarrhoea
|
EP2255813A1
(de)
*
|
2009-05-29 |
2010-12-01 |
The Royal College of Surgeons in Ireland |
Ursodeoxycholsäurederivate zur Behandlung von Diarrhöe
|
US8258485B2
(en)
*
|
2010-08-30 |
2012-09-04 |
Media Lario Srl |
Source-collector module with GIC mirror and xenon liquid EUV LPP target system
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
CA3028207A1
(en)
*
|
2012-06-19 |
2013-12-27 |
Intercept Pharmaceuticals, Inc. |
Preparation, uses and solid forms of obeticholic acid
|
WO2014066819A1
(en)
*
|
2012-10-26 |
2014-05-01 |
Intercept Pharmaceuticals, Inc. |
Process for preparing bile acid derivatives
|
ES2847002T3
(es)
|
2013-05-14 |
2021-07-30 |
Intercept Pharmaceuticals Inc |
Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide
|
AU2014278833A1
(en)
|
2013-06-13 |
2016-01-07 |
Fast Forward Pharmaceuticals B.V. |
CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
SI3043865T1
(sl)
|
2013-09-11 |
2021-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
|
SI3594348T1
(sl)
|
2013-11-22 |
2022-04-29 |
Mina Therapeutics Limited |
Sestavki kratko aktivirajoče rna c/ebp alfa in postopki uporabe
|
JP6820253B2
(ja)
*
|
2014-05-29 |
2021-01-27 |
バール ファーマシューティカルズ ソチエタ レスポンサビリタ リミタータ |
Fxb及びtgr5/gpbar1介在性疾患の治療及び/又は予防に使用するためのコラン誘導体
|
MX2017005935A
(es)
|
2014-11-06 |
2018-01-11 |
Enanta Pharm Inc |
Análogos de ácido biliar como agonistas fxr/tgr5 y métodos de uso de los mismos.
|
PL3221333T3
(pl)
*
|
2014-11-19 |
2020-01-31 |
NZP UK Limited |
Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
|
EA033427B1
(ru)
|
2014-11-19 |
2019-10-31 |
Nzp Uk Ltd |
6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
|
CN107108687B
(zh)
|
2014-11-19 |
2019-10-29 |
Nzp英国有限公司 |
作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇
|
KR102527821B1
(ko)
|
2014-11-19 |
2023-05-02 |
엔제트피 유케이 리미티드 |
스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
MX2017006833A
(es)
|
2014-11-26 |
2018-02-13 |
Enanta Pharm Inc |
Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
|
ES2905872T3
(es)
|
2015-02-06 |
2022-04-12 |
Intercept Pharmaceuticals Inc |
Composiciones farmacéuticas para terapia combinada
|
EP3256134A4
(de)
|
2015-02-11 |
2018-10-03 |
Enanta Pharmaceuticals, Inc. |
Gallensäureanaloga als fxr/tgr5-agonisten und verfahren zur verwendung davon
|
CN105985396A
(zh)
*
|
2015-02-16 |
2016-10-05 |
苏州泽璟生物制药有限公司 |
氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
|
SI3277286T1
(sl)
|
2015-03-31 |
2021-09-30 |
Enanta Pharmaceuticals, Inc. |
Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo
|
US10894054B2
(en)
|
2015-04-07 |
2021-01-19 |
Intercept Pharmaceuticals, Inc. |
FXR agonist compositions for combination therapy
|
CN105777836A
(zh)
*
|
2015-04-09 |
2016-07-20 |
厦门蔚扬药业有限公司 |
奥贝胆酸的多晶型物及其制备方法
|
CN107531743B
(zh)
*
|
2015-04-29 |
2020-05-05 |
正大天晴药业集团股份有限公司 |
鹅去氧胆酸衍生物
|
EP3124080A1
(de)
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetische gallsäurederivate zur injektionslipolyse
|
CN105175473B
(zh)
*
|
2015-08-19 |
2018-12-21 |
丽珠医药集团股份有限公司 |
一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
|
CN106632564B
(zh)
*
|
2015-10-30 |
2021-04-13 |
苏州泽璟生物制药股份有限公司 |
奥贝胆酸盐及其无定形物和药物组合物
|
CN106749466B
(zh)
*
|
2015-11-23 |
2019-05-21 |
南京济群医药科技股份有限公司 |
一种高纯度奥贝胆酸的制备方法
|
CN105315320B
(zh)
*
|
2015-11-30 |
2017-03-08 |
山东省药学科学院 |
一种制备奥贝胆酸的方法
|
CN106810586A
(zh)
*
|
2015-12-01 |
2017-06-09 |
中美华世通生物医药科技(武汉)有限公司 |
奥贝胆酸晶型ⅱ及其制备方法和用途
|
CN106810587A
(zh)
*
|
2015-12-01 |
2017-06-09 |
中美华世通生物医药科技(武汉)有限公司 |
制备无定型奥贝胆酸的方法
|
CN109071593B
(zh)
|
2016-01-28 |
2021-01-15 |
正大天晴药业集团股份有限公司 |
甾体类衍生物fxr激动剂
|
US20170233431A1
(en)
|
2016-02-17 |
2017-08-17 |
City Of Hope |
Bile acid derivatives and methods for synthesis and use
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
US11161871B2
(en)
*
|
2016-03-31 |
2021-11-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Crystalline form of obeticholic acid and preparation method therefor
|
TW201738254A
(zh)
*
|
2016-04-19 |
2017-11-01 |
英特賽普醫藥品公司 |
奧貝膽酸及其衍生物之製備方法
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
EA038580B9
(ru)
*
|
2016-05-18 |
2021-10-05 |
Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. |
Агонист fxr, представляющий собой производное стероидов
|
WO2017207648A1
(en)
|
2016-05-31 |
2017-12-07 |
Bionice, S.L.U |
Process and intermediates for the preparation of obeticholic acid and derivatives thereof
|
WO2018010651A1
(zh)
*
|
2016-07-13 |
2018-01-18 |
江苏恒瑞医药股份有限公司 |
一种奥贝胆酸及其中间体的制备方法
|
US10584145B2
(en)
|
2016-11-29 |
2020-03-10 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonylurea bile acid derivatives
|
WO2018152171A1
(en)
|
2017-02-14 |
2018-08-23 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr agonists and methods of use thereof
|
BR112019017312A2
(pt)
|
2017-02-21 |
2020-04-14 |
Genfit |
combinação de um agonista de ppar com um agonista de fxr
|
AU2018230350A1
(en)
*
|
2017-03-08 |
2019-09-26 |
Intercept Pharmaceuticals, Inc |
Crystalline forms of obeticholic acid
|
JP2020515564A
(ja)
|
2017-03-30 |
2020-05-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
|
KR102624997B1
(ko)
|
2017-04-07 |
2024-01-12 |
이난타 파마슈티칼스, 인코포레이티드 |
술포닐 카바메이트 담즙산 유도체의 제조 방법
|
US11339147B2
(en)
|
2017-05-26 |
2022-05-24 |
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
Lactam compound as FXR receptor agonist
|
CN109021056B
(zh)
*
|
2017-06-09 |
2021-03-09 |
博瑞生物医药(苏州)股份有限公司 |
法尼酯x受体激动剂
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
WO2020039449A1
(en)
|
2018-08-24 |
2020-02-27 |
Solara Active Pharma Sciences Limited |
An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
|
KR20210097158A
(ko)
*
|
2018-11-26 |
2021-08-06 |
씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 |
Fxr 작용제의 고체 형태, 결정 형태, 및 결정 형태 a, 및 이의 제조방법 및 이의 적용
|
EP3976049A1
(de)
|
2019-05-30 |
2022-04-06 |
Intercept Pharmaceuticals, Inc. |
Pharmazeutische zusammensetzungen mit einem fxr-agonisten und ein fibrat zur verwendung bei der behandlung von cholestatischer lebererkrankung
|
WO2021009332A1
(en)
|
2019-07-18 |
2021-01-21 |
Enyo Pharma |
Method for decreasing adverse-effects of interferon
|
WO2021023100A1
(zh)
*
|
2019-08-06 |
2021-02-11 |
杜心赟 |
脱氧胆酸类化合物、药物组合物及其用途
|
AU2021207253A1
(en)
|
2020-01-15 |
2022-06-09 |
Centre National De La Recherche Scientifique |
Use of FXR agonists for treating an infection by hepatitis D virus
|
AU2022209084A1
(en)
|
2021-01-14 |
2023-08-10 |
Centre Leon Bérard |
Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
|
EP4329761A1
(de)
|
2021-04-28 |
2024-03-06 |
ENYO Pharma |
Starke potenzierung von tlr3-agonisten-effekten mit fxr-agonisten als kombinierte behandlung
|